JP4145314B2 - 腫瘍細胞成長阻害のための組成物及び方法 - Google Patents

腫瘍細胞成長阻害のための組成物及び方法 Download PDF

Info

Publication number
JP4145314B2
JP4145314B2 JP2005229454A JP2005229454A JP4145314B2 JP 4145314 B2 JP4145314 B2 JP 4145314B2 JP 2005229454 A JP2005229454 A JP 2005229454A JP 2005229454 A JP2005229454 A JP 2005229454A JP 4145314 B2 JP4145314 B2 JP 4145314B2
Authority
JP
Japan
Prior art keywords
amino acid
sequence
polypeptide
acid sequence
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2005229454A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006025793A (ja
JP2006025793A5 (https=
Inventor
ベーカー，ケヴィン，ピー．
ゴッダード，オードリー
ガーニー，オースティン，エル．
ヘベール，キャロライン
ヘンゼル，ウィリアム
カバコフ，ローナ，シー．
シェルトン，デイビッド，エル．
スミス，ヴィクトリア
ワタナベ，コリン，ケー．
ウッド，ウィリアム，アイ．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1999/012252 external-priority patent/WO1999063088A2/en
Priority claimed from PCT/US1999/020111 external-priority patent/WO2000012708A2/en
Priority claimed from PCT/US1999/020594 external-priority patent/WO2000015666A2/en
Priority claimed from PCT/US1999/028313 external-priority patent/WO2000032221A2/en
Priority claimed from PCT/US1999/028634 external-priority patent/WO2000036102A2/en
Priority claimed from PCT/US1999/028551 external-priority patent/WO2000053750A1/en
Priority claimed from PCT/US1999/030095 external-priority patent/WO2000037640A2/en
Priority claimed from PCT/US1999/030999 external-priority patent/WO2001005836A1/en
Priority claimed from PCT/US2000/000376 external-priority patent/WO2000053755A2/en
Priority claimed from PCT/US2000/003565 external-priority patent/WO2001053486A1/en
Priority claimed from PCT/US2000/004342 external-priority patent/WO2000078961A1/en
Priority claimed from PCT/US2000/004341 external-priority patent/WO2000053756A2/en
Priority claimed from PCT/US2000/005841 external-priority patent/WO2000053758A2/en
Priority claimed from PCT/US2000/006319 external-priority patent/WO2000053760A2/en
Priority claimed from PCT/US2000/006884 external-priority patent/WO2001005972A1/en
Priority claimed from PCT/US2000/008439 external-priority patent/WO2000073454A1/en
Priority claimed from PCT/US2000/013705 external-priority patent/WO2000073445A2/en
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of JP2006025793A publication Critical patent/JP2006025793A/ja
Publication of JP2006025793A5 publication Critical patent/JP2006025793A5/ja
Application granted granted Critical
Publication of JP4145314B2 publication Critical patent/JP4145314B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2005229454A 1999-06-02 2005-08-08 腫瘍細胞成長阻害のための組成物及び方法 Expired - Lifetime JP4145314B2 (ja)

Applications Claiming Priority (23)

Application Number Priority Date Filing Date Title
PCT/US1999/012252 WO1999063088A2 (en) 1998-06-02 1999-06-02 Membrane-bound proteins and nucleic acids encoding the same
US14065099P 1999-06-22 1999-06-22
US14103799P 1999-06-23 1999-06-23
US14475899P 1999-07-20 1999-07-20
PCT/US1999/020111 WO2000012708A2 (en) 1998-09-01 1999-09-01 Further pro polypeptides and sequences thereof
PCT/US1999/020594 WO2000015666A2 (en) 1998-09-10 1999-09-08 Compositions and methods for the treatment of tumors
US16250699P 1999-10-29 1999-10-29
PCT/US1999/028313 WO2000032221A2 (en) 1998-12-01 1999-11-30 Promotion or inhibition of angiogenesis and cardiovascularization
PCT/US1999/028634 WO2000036102A2 (en) 1998-12-16 1999-12-01 Secreted and transmembrane polypeptides and nucleic acids encoding the same
PCT/US1999/028551 WO2000053750A1 (en) 1999-03-08 1999-12-02 Compositions and methods for the treatment of tumors
US17026299P 1999-12-09 1999-12-09
PCT/US1999/030095 WO2000037640A2 (en) 1998-12-22 1999-12-16 Compositions and methods for the treatment of tumor
PCT/US1999/030999 WO2001005836A1 (en) 1999-07-20 1999-12-20 Polypeptidic compositions and methods for the treatment of tumors
PCT/US2000/000376 WO2000053755A2 (en) 1999-03-08 2000-01-06 Compositions and methods for the treatment of tumor
PCT/US2000/003565 WO2001053486A1 (en) 1999-03-08 2000-02-11 Compositions and methods for the treatment of tumor
PCT/US2000/004342 WO2000078961A1 (en) 1999-06-23 2000-02-18 Secreted and transmembrane polypeptides and nucleic acids encoding the same
PCT/US2000/004341 WO2000053756A2 (en) 1999-03-08 2000-02-18 Secreted and transmembrane polypeptides and nucleic acids encoding the same
PCT/US2000/005841 WO2000053758A2 (en) 1999-03-08 2000-03-02 Compositions and methods for the treatment of immune related diseases
US18720200P 2000-03-03 2000-03-03
PCT/US2000/006319 WO2000053760A2 (en) 1999-03-12 2000-03-10 Method of preventing the death of retinal neurons and treating ocular diseases
PCT/US2000/006884 WO2001005972A1 (en) 1999-07-20 2000-03-15 Compositions and methods for the treatment of immune related diseases
PCT/US2000/008439 WO2000073454A1 (en) 1999-06-02 2000-03-30 Secreted and transmembrane polypeptides and nucleic acids encoding the same
PCT/US2000/013705 WO2000073445A2 (en) 1999-06-02 2000-05-17 Interleukin-1-receptor associated kinase-3 (irak3)

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2001500672A Division JP2003524406A (ja) 1999-06-02 2000-05-30 腫瘍細胞成長阻害のための組成物及び方法

Related Child Applications (3)

Application Number Title Priority Date Filing Date
JP2006225771A Division JP4074645B2 (ja) 1999-06-02 2006-08-22 腫瘍細胞成長阻害のための組成物及び方法
JP2006225770A Division JP4072181B2 (ja) 1999-06-02 2006-08-22 腫瘍細胞成長阻害のための組成物及び方法
JP2006225772A Division JP2007029098A (ja) 1999-06-02 2006-08-22 腫瘍細胞成長阻害のための組成物及び方法

Publications (3)

Publication Number Publication Date
JP2006025793A JP2006025793A (ja) 2006-02-02
JP2006025793A5 JP2006025793A5 (https=) 2007-07-12
JP4145314B2 true JP4145314B2 (ja) 2008-09-03

Family

ID=40532223

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2005229454A Expired - Lifetime JP4145314B2 (ja) 1999-06-02 2005-08-08 腫瘍細胞成長阻害のための組成物及び方法
JP2006225772A Pending JP2007029098A (ja) 1999-06-02 2006-08-22 腫瘍細胞成長阻害のための組成物及び方法
JP2006225771A Expired - Lifetime JP4074645B2 (ja) 1999-06-02 2006-08-22 腫瘍細胞成長阻害のための組成物及び方法
JP2006225770A Expired - Lifetime JP4072181B2 (ja) 1999-06-02 2006-08-22 腫瘍細胞成長阻害のための組成物及び方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2006225772A Pending JP2007029098A (ja) 1999-06-02 2006-08-22 腫瘍細胞成長阻害のための組成物及び方法
JP2006225771A Expired - Lifetime JP4074645B2 (ja) 1999-06-02 2006-08-22 腫瘍細胞成長阻害のための組成物及び方法
JP2006225770A Expired - Lifetime JP4072181B2 (ja) 1999-06-02 2006-08-22 腫瘍細胞成長阻害のための組成物及び方法

Country Status (8)

Country Link
EP (1) EP1185648B1 (https=)
JP (4) JP4145314B2 (https=)
AT (1) ATE357518T1 (https=)
CA (1) CA2373915A1 (https=)
DK (1) DK1185648T3 (https=)
ES (1) ES2287020T3 (https=)
PT (1) PT1185648E (https=)
WO (1) WO2000073348A2 (https=)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020192752A1 (en) 1998-09-09 2002-12-19 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US6623923B1 (en) 1998-12-23 2003-09-23 Corixa Corporation Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
US6593133B1 (en) * 1998-07-06 2003-07-15 Nsgene A/S Neurotrophic factors
US20020055467A1 (en) * 1998-07-06 2002-05-09 Johansen Teit E. Novel neurotrophic factors
US20070014787A1 (en) 1998-07-15 2007-01-18 Human Genome Sciences, Inc. 71 human secreted proteins
CA2356987A1 (en) * 1998-12-23 2000-06-29 Corixa Corporation Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
ATE363489T1 (de) * 1999-03-08 2007-06-15 Genentech Inc In tumoren vervielfältigte gensequenzen und deren diagnostische verwendungen
US7282562B2 (en) 1999-08-31 2007-10-16 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
EP1208201B9 (en) * 1999-08-31 2009-08-19 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
EP1220919A2 (en) * 1999-09-29 2002-07-10 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Metastasis-associated antigen c4.4a
CA2396036A1 (en) * 1999-12-30 2001-07-12 Corixa Corporation Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
AU2001255168A1 (en) * 2000-03-03 2001-09-17 Genentech Inc. Compositions and methods for the treatment of immune related diseases
AU2001249608A1 (en) * 2000-03-28 2001-10-08 Beth Israel Deaconess Medical Center Bladder cancer-specific peptides for diagnosis and therapy
US7442370B2 (en) 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
US7276580B2 (en) 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
US6734289B2 (en) 2001-03-29 2004-05-11 The University Of Chicago Gastrokines and derived peptides including inhibitors
US7629317B2 (en) 2001-03-29 2009-12-08 The University Of Chicago Control of growth and repair of gastro-intestinal tissues by gastrokines and inhibitors
EP2341152A1 (en) 2001-09-14 2011-07-06 Clinical Genomics Pty. Ltd Nucleic acid markers for use in determining predisposition to neoplasm and/or adenoma
WO2003088808A2 (en) 2002-04-16 2003-10-30 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
AU2002335054A1 (en) * 2001-12-19 2003-07-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2003104438A2 (en) * 2002-06-11 2003-12-18 Avalon Pharmaceuticals, Inc. Cancer-linked gene as target for chemotherapy
EP1562587A4 (en) * 2002-09-11 2006-07-19 Genentech Inc NEW COMPOSITIONS AND METHOD FOR THE TREATMENT OF IMMUNOMOTICS
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
WO2005032476A2 (en) * 2003-09-30 2005-04-14 Massachusetts Institute Of Technology Methods and compositions for cpg15-2
DE102004024617A1 (de) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
NZ553420A (en) 2004-08-19 2010-02-26 Biogen Idec Inc Refolding transforming growth factor beta family proteins
US8017576B2 (en) 2005-05-10 2011-09-13 The University Of Chicago Methods and compositions to treat mucositis
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
US7884078B2 (en) 2006-02-10 2011-02-08 Massachusetts Institute Of Technology CPG15 compounds as insulin receptor and insulin-like growth factor receptor agonists
TWI501774B (zh) 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
JP5583005B2 (ja) 2007-05-01 2014-09-03 バイオジェン・アイデック・エムエイ・インコーポレイテッド 血管新生を増大させるための組成物および方法
LT2398902T (lt) 2009-02-20 2023-12-27 Astellas Pharma Inc. Vėžio diagnostikos ir gydymo būdai bei kompozicijos
NZ716587A (en) 2009-11-11 2017-10-27 Ganymed Pharmaceuticals Ag Antibodies specific for claudin 6 (cldn6)
EP2404936A1 (en) 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
US9321842B2 (en) 2011-05-13 2016-04-26 Ganymed Pharmaceuticals Ag Antibodies for treatment of cancer
JP5891561B2 (ja) * 2011-06-03 2016-03-23 学校法人自治医科大学 ミトコンドリア膜タンパク質群およびそれらをコードする遺伝子群
WO2013167153A1 (en) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
WO2015014376A1 (en) 2013-07-31 2015-02-05 Biontech Ag Diagnosis and therapy of cancer involving cancer stem cells
CN115197301B (zh) * 2022-06-10 2024-07-16 北京师范大学 用于胞内钙信号检测及相关药物筛选的钙指示工具及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ226799A (en) * 1987-11-06 1991-08-27 Oncogen Breast cancer inhibitory factor and method for inhibiting proliferation of neoplastic cells and compositions therefor
US5814307A (en) * 1989-04-10 1998-09-29 Bristol-Myers Squibb Company Method for regulating cell growth, leukocyte differentiation and tumor cell growth using Oncostatin M to stimulate synthesis of IL-6
US5416192A (en) * 1990-04-03 1995-05-16 Bristol-Myers Squibb Company Epithelins: novel cysteine-rich growth modulating proteins
WO1999014327A2 (en) * 1997-09-17 1999-03-25 Genentech, Inc. Genes amplified in tumours, antibodies against the proteins coded thereby, and their use in diagnosis and treatment of cancer
AU4694696A (en) * 1996-01-04 1997-08-01 Human Genome Sciences, Inc. Transforming growth factor alpha hiii
AU9283298A (en) * 1997-10-08 1999-04-27 Protegene Inc. Human proteins having transmembrane domains and cdnas encoding these proteins
IL141426A0 (en) * 1998-09-10 2002-03-10 Genentech Inc Compositions and methods for the treatment of tumor

Also Published As

Publication number Publication date
EP1185648A2 (en) 2002-03-13
JP2007029098A (ja) 2007-02-08
ATE357518T1 (de) 2007-04-15
JP4072181B2 (ja) 2008-04-09
JP2006025793A (ja) 2006-02-02
WO2000073348A2 (en) 2000-12-07
ES2287020T3 (es) 2007-12-16
PT1185648E (pt) 2007-06-29
WO2000073348A3 (en) 2001-07-05
CA2373915A1 (en) 2000-12-07
JP2007014346A (ja) 2007-01-25
JP2007029097A (ja) 2007-02-08
EP1185648B1 (en) 2007-03-21
DK1185648T3 (da) 2007-07-30
JP4074645B2 (ja) 2008-04-09

Similar Documents

Publication Publication Date Title
JP4145314B2 (ja) 腫瘍細胞成長阻害のための組成物及び方法
JP4037876B2 (ja) 腫瘍性細胞成長阻害のための組成物及び方法
JP4451059B2 (ja) 分泌及び膜貫通ポリペプチドとそれをコードする核酸
JP2004000008A (ja) 新規なポリペプチド及びそれをコードする核酸
JP2008301810A (ja) 免疫関連疾患を治療するための組成物及び方法
JP2003505350A5 (https=)
JP2002531092A (ja) 腫瘍性細胞成長阻害のための組成物及び方法
JP4280444B2 (ja) 腫瘍性細胞成長阻害のための組成物及び方法
JP2003530082A6 (ja) 免疫関連疾患を治療するための組成物及び方法
EP1820859B9 (en) Methods and compositions for inhibiting neoplastic cell growth
JP2002527452A (ja) 腫瘍性細胞成長阻害のための組成物及び方法
JP2003524406A (ja) 腫瘍細胞成長阻害のための組成物及び方法
EP1870464A2 (en) Methods and compositions for inhibiting neoplastic cell growth
JP2007238619A (ja) 腫瘍性細胞成長阻害のための組成物及び方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070530

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070530

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070807

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20071109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20071213

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20071213

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20071217

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20071225

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080324

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080331

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080424

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20080523

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20080617

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

Ref document number: 4145314

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110627

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110627

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120627

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120627

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130627

Year of fee payment: 5

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term